> ## Content Index
> Fetch the complete content index at: https://www.pennystocks.news/llms.txt
> Use this file to discover other available public pages before exploring further.

# This Antibiotic Biotech Is Out of Second Chances at Nasdaq
- URL: https://www.pennystocks.news/labt-this-antibiotic-biotech-is-out-of-second-chances-at-nas/
- Published: 2026-11-22T18:00:35.000Z
- Updated: 2026-11-22T18:00:35.000Z
- Description: Lakewood-Amedex did a 1-for-10 reverse split in June. That split is now the reason Nasdaq will not give it the standard compliance period to fix its share price.
- Author: PennyStocksNews Team
- Tags: nasdaq, LABT

On June 22, Lakewood-Amedex turned every ten of its shares into one. By November, that move had become the reason Nasdaq would not give the company a compliance period.

Lakewood-Amedex Biotherapeutics Inc. NASDAQ: LABT 

Nasdaq's listing team sent a delisting notice on November 10, applying a rule that bars the standard compliance period for any company that has done a reverse split within the prior year. **Lakewood-Amedex had done one that June.** The stock had been **below $1.00 for 30 consecutive business days** — September 29 through November 9 — before the notice arrived.

That compliance period normally gives a company time to bring its price back above the minimum before trading is suspended. Here, the reverse split within the prior year had closed that path. Without a hearing request by November 17, trading was set to be suspended at the open of November 19.

Shares closed 15.03% higher at $0.2449, on dollar volume of about $14.8 million.

The company says it **intends to request a hearing** before a Nasdaq panel, which would pause the suspension while the panel reviews its case. At the hearing, it plans to present a plan to regain compliance — one the filing says **may include a reverse split.**

The filing says there is no assurance the panel will grant continued listing or that the company will regain compliance.